NCT00029380 is a Phase 2 clinical trial of Sangstat in Hematologic Diseases, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT00029380?

NCT00029380 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What drugs are being tested in NCT00029380?

Interventions in NCT00029380: Sangstat, Cyclophosphamide, Busulfan, Mycophenolate Mofetil, Cyclosporine, Cord Blood Transplantation.

What condition does NCT00029380 study?

NCT00029380 studies Hematologic Diseases, Anemia, Sickle Cell, Beta-Thalassemia, Hematopoietic Stem Cell Transplantation.

Is NCT00029380 still recruiting?

NCT00029380 is currently completed. Last updated 28 July 2016.

Last reviewed 2016-07-28 · How we verify

NCT00029380

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sibling Donor Cord Blood Banking and Transplantation

Completed Phase 2 Last updated 28 July 2016

What this trial tests

Phase 2 trial testing Sangstat in Hematologic Diseases in 30 participants. Completed in 1 August 2006.

Timeline

1 January 1999

Primary endpoint
1 August 2006

1 August 2006

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	30
Start date	1 January 1999
Primary completion	1 August 2006
Estimated completion	1 August 2006
Sites	15 locations across United States, Canada

Drugs / interventions tested

Sangstat — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Busulfan — full drug profile →
Mycophenolate Mofetil (MYCOPHENOLATE MOFETIL) — full drug profile →
Cyclosporine (cyclosporine) — full drug profile →
Cord Blood Transplantation

Conditions studied

Hematologic Diseases — all drugs for Hematologic Diseases →
Anemia, Sickle Cell — all drugs for Anemia, Sickle Cell →
Beta-Thalassemia — all drugs for Beta-Thalassemia →
Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

Adults 3 to 14, any sex, with Hematologic Diseases or Anemia, Sickle Cell. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hematologic parameters
GVHD

Sponsor's own description

This study will develop a national cord blood bank for siblings of patients with hemoglobinopathies and thalassemia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease.
Leonard A, Furstenau D, Abraham A, Darbari DS, et al · · 2023 · cited 15× · PMID 36240296 · DOI 10.1182/bloodadvances.2022008137

Verify or expand the search:

Other recruiting trials for Hematologic Diseases

Currently open trials in the same condition.

NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting
NCT05414045 — Autologous Testicular Tissue Transplantation · NA · recruiting
NCT06613425 — Clinical Study of Combined Platelet Transfusion · Phase 4 · recruiting
NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00029380 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: 28 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00029380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing